Related Experiment Video
Updated: Jul 17, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Chronic inflammatory demyelinating polyneuropathies: current treatment strategies
Thomas B Toothaker1, Thomas H Brannagan
1Department of Neurology, Weill Medical College of Cornell University, Peripheral Neuropathy Center, New York, NY 10022, USA.
Current Neurology and Neuroscience Reports
|January 16, 2007
Summary
Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an immune-mediated disease often underdiagnosed. Early treatment with IVIg, plasmapheresis, or corticosteroids is crucial for functional recovery and preventing nerve damage.
Area of Science:
- Neurology
- Immunology
- Clinical Medicine
Background:
- Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an immune-mediated neurological disorder.
- Diagnosis is challenging due to heterogeneous presentations and limited diagnostic criteria.
- Early intervention is vital to prevent irreversible axonal loss and enhance functional recovery.
Purpose of the Study:
- To review the diagnostic challenges and treatment modalities for CIDP.
- To highlight the importance of early recognition and management.
- To discuss the evidence base for various CIDP therapies.
Main Methods:
- Review of existing literature on CIDP diagnosis and treatment.
- Analysis of evidence for primary and secondary treatment options.
- Comparison of efficacy and considerations for treatment selection.
Main Results:
- Intravenous immunoglobulin (IVIg) and plasmapheresis have strong supporting evidence.
- Corticosteroids are standard despite less definitive evidence.
- No significant difference in efficacy found among IVIg, plasmapheresis, and corticosteroids.
- Chemotherapeutic and immunosuppressive agents show potential but require more evidence.
Conclusions:
- CIDP requires early diagnosis and treatment to improve outcomes.
- Treatment choice often depends on availability and side-effect profiles.
- Long-term management is necessary to sustain response and prevent relapses.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...